GlaxoSmithKline S.A.E (EGX:BIOC)
Egypt · Delayed Price · Currency is EGP 260.03
-13.41 (-4.90%)
At close: Oct 22, 2026
GlaxoSmithKline S.A.E Revenue
GlaxoSmithKline S.A.E had revenue of 958.94M EGP in the quarter ending June 30, 2026, with 7.63% growth. This brings the company's total for the last twelve months to 3.62B, up 2.80% year-over-year. In the year 2025, GlaxoSmithKline S.A.E had annual revenue of 3.73B with 24.73% growth. That makes GlaxoSmithKline S.A.E the 25,918th largest company in the world by revenue and 80th in Egypt.
Revenue (ttm)
3.62B
Revenue Growth
+2.80%
P/S Ratio
6.00
Revenue / Employee
n/a
Employees
n/a
Market Cap
21.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.73B | 739.68M | 24.73% |
| Dec 31, 2024 | 2.99B | 750.60M | 33.51% |
| Dec 31, 2023 | 2.24B | 416.99M | 22.87% |
| Dec 31, 2022 | 1.82B | 11.19M | 0.62% |
| Dec 31, 2021 | 1.81B | -180.79M | -9.07% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.